AIM ImmunoTech Inc.

AIM · NYSE AMERICAN

AIM ImmunoTech Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.

Follow Add to Watchlist Ask Question

NYSE AMERICAN AIM Coverage Bootstrap NYSE American AIM ImmunoTech Inc.

Latest ReportMay 27, 2026AIM ImmunoTech Inc.: the filing proof gates that matter nowView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 company reports

Add tags

Latest Thesis

AIM ImmunoTech Inc.: the filing proof gates that matter now

AIM ImmunoTech Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.

May 27, 2026Research reportSlides available

Read report Open slides Discussion (0)

AIM ImmunoTech Inc.ImmunoTech Inc.: the filing proof gates that matter nowMay 27, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

AIM ImmunoTech Inc.: the filing proof gates that matter nowAIM ImmunoTech Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.NYSE AMERICANMay 27, 2026Research reportRead Slides